Minor ischemic stroke or high-risk transient ischemic attack
Conditions
Interventions
The low-dose group:Will receive ticagrelor 45 mg BID (Day 1 90 mg taken at a draught) plus aspirin (100 mg daily) for 21 days, followed by ticagrelor 45 mg BID monotherapy for the remaining 69 days.
The standard-dose group:will receive ticagrelor 90 mg BID (Day 1 180 mg taken at a draught) plus aspirin (100 mg daily) for 21 days, followed by ticagrelor 90 mg BID monotherapy for the remaining 69 d
Sponsors
Yichang Central People's Hospital
Eligibility
Sex/Gender
All
Age
40 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.The patient's age is no less than 40 years old. 2. Diagnosed as non-cardiogenic acute non-disabling ischemic stroke (NIHSS score =4). 3. The time from symptom onset to randomization is less than or equal to 72 hours. 4. Confirmed by genetic testing to carry the CYP2C19 loss-of-function allele.
Exclusion criteria
Exclusion criteria: 1.There are contraindications to aspirin or ticagrelor. 2. Has a history of intracranial hemorrhage. 3. Long-term anticoagulant therapy is required. 4. Active bleeding or high risk of bleeding. 5. Have undergone major surgery within the past 30 days. 6. Severe liver and kidney dysfunction (Child-Pugh grade C or CKD stage 3 or above). 7. Pregnancy or lactation. 8. Participate in other clinical trials that may interfere with this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CYP2C19 loss-of-function allele; | — |
Countries
China
Contacts
Public ContactTao Wang
Wujia Campus of Yichang Central People's Hospital
Outcome results
None listed